Lopinavir/ritonavir (ABT-378/r)

@article{Qazi2002Lopinavirritonavir,
  title={Lopinavir/ritonavir (ABT-378/r)},
  author={Nadeem A Qazi and Anton L Pozniak and John F. Morlese},
  journal={Expert Opinion on Pharmacotherapy},
  year={2002},
  volume={3},
  pages={315 - 327}
}
Despite major advances in HIV research, eradication of HIV from the body is not yet possible. However, current antiretroviral (ARV) therapy can achieve disease control via viral suppression below the limits of detection of currently available assays. This has led to a marked decline in morbidity and mortality associated with the development of opportunistic infections and malignancies. Since viral suppression appears to be the most achievable goal of current therapy, there arises a need for new… Expand
Monotherapy with lopinavir/ritonavir
TLDR
It may be warranted to conduct trials to investigate the cost-effectiveness of lopinavir/ritonavir monotherapy as second-line therapy in resource-constrained settings where virologic monitoring is not feasible. Expand
Lopinavir: the old champion
TLDR
This article summarizes the main clinical studies with lopinavir and discusses its particular characteristics as well as its possible current role in antiretroviral therapy. Expand
Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment
TLDR
An overview of the properties of LPV/r and the experience with its use in HIV-infected adults and adolescents is provided and its high genetic barrier to resistance favours long-term efficacy. Expand
New anti-HIV protease inhibitors provide more treatment options.
  • J. Nadler
  • Medicine
  • AIDS patient care and STDs
  • 2003
TLDR
Two new PIs, atazanavir and 908, may offer salvageable PI treatment options and may also address issues of potency, tolerability, and convenience by requiring fewer pills and causing fewer lipid and glucose perturbations than current PI options. Expand
A review of low-dose ritonavir in protease inhibitor combination therapy.
TLDR
Evidence suggests that increased exposure to protease inhibitors is clinically relevant and additional study will elucidate the advantages and disadvantages of twice-daily, low-dose ritonavir-boosted regimens and determine whether once-daily regimens based on this principle will have a lasting role in clinical practice. Expand
Combination Antiviral Therapy with Lopinavir/Ritonavir, Arbidol and Interferon-α1b for COVID-19
TLDR
This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection. Expand
Inhibitors of HIV-1 protease: 10 years after
TLDR
A review of the pharmacology and interactions of these agents with other drugs is presented, with emphasis on how these pharmacological interferences may improve the clinical use of antivirals, or how side effects due to PI drugs may be managed better by taking them into account. Expand
Review: Cross-Resistance Patterns Among HIV Protease Inhibitors
TLDR
Development of rational treatment strategies that recognize specific patterns of cross-resistance among PIs are needed to help clinicians choose the most appropriate PI, based on genotypic and phenotypic resistance testing. Expand
Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
TLDR
A review on the pharmacology and interactions of these agents with other drugs is presented, with emphasis on how these pharmacological interferences may improve the clinical use of antivirals, or how side effects due to these drugs may be managed better by taking them into account. Expand
Translating Efficacy into Effectiveness in Antiretroviral Therapy
TLDR
Clinicians and HIV-infected patients recognise that there are several other characteristics of an ARV regimen that are equally important contributors to its effectiveness. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 62 REFERENCES
Use of HIV protease inhibitors as pharmacoenhancers.
TLDR
Using a boosted PI, in the absence of comparative data on resistance profiles of boosted regimens, should be considered differently from dual-PI combinations, where there is exposure to 2 active PIs. Expand
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
TLDR
It is suggested that twice-daily indinavir-ritonavir and, to a lesser extent, amprenavir-ritchavir may be effective for many patients with viruses resistant to protease inhibitors. Expand
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
TLDR
Clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient, and several criteria must be met. Expand
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
TLDR
The potential utility of ABT-378 as a therapeutic intervention against AIDS is demonstrated by using the X-ray crystal structure of the complex of HIV protease and ritonavir to design a potent protease inhibitor which has a diminished interaction with Val 82. Expand
Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.
TLDR
The magnitude of this interaction suggests a lower starting dose of sildenafil may be more appropriate in this clinical setting, and the mechanism of increase is indinavir inhibition of the hepatic metabolism of s BildenafIL. Expand
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
TLDR
Five resistant variants isolated from patients undergoing therapy with the protease inhibitor MK-639 exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors, suggesting that com-bination therapy with multiple protease inhibition may not prevent loss of antiviral activity resulting from resistance selection. Expand
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
TLDR
The activity and durable suppression of HIV-1 observed in this study is probably attributable to the observed tolerability profile and the achievement of high ABT-378 plasma concentrations. Expand
Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.
TLDR
In vivo testing of protease inhibitors against wild-type and mutant HIV in the presence of human serum suggested that the activity of ABT-378 is affected predominantly by binding to alpha1-acid glycoprotein (AGP) while theActivity of ritonavir is modulated by both AGP and albumin. Expand
Human Immunodeficiency Virus Protease Inhibitors
TLDR
Human immunodeficiency virus (HIV) protease inhibitors have revolutionized the treatment of individuals infected with this pathogen, and all must be considered when selecting the drugs for therapeutic use in humans. Expand
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
TLDR
Analysis of the HIV protease gene from the plasma of HIV–infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitors ritonavir, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression. Expand
...
1
2
3
4
5
...